View source for Dynepo

'''Dynepo''' is a form of pharmaceutical [[erythropoietin]] (EPO) under development as a pharmaceutical product by [[Shire Pharmaceuticals Group|Shire Pharmaceuticals]]. The first development steps were performed by HMR and Aventis. Aventis obtained the license in Europe in 2002. The company expects to launch the product in Europe in 2006, although patents held by the [[United States of America|American]] [[biotechnology]] company [[Amgen|Amgen, Inc.]] may preclude its sale in the United States.

EPO is a natural human hormone that stimulates formation of [[red blood cell]]s. Pharmaceutical EPO, made via [[recombinant DNA technology]] is used to treat [[anemia]], but it has also been used by [[blood doping|doping]] athletes to improve their aerobic performance and stamina.

Unlike existing forms of pharmaceutical EPO manufactured in [[cell culture|cultured animal cells]], Dynepo is to be made in cultured human cells. It is therefore expected to have an authentic human form of [[sialic acid]] and other [[oligosaccharide]] residues. This characteristic may make it a longer-acting product than existing brands, but clinical data have not yet been made public. It should also make Dynepo undetectable in the existing urine test for EPO used to detect doping by athletes.  However, on September 28, 2007, the French sports newspaper ''L'Equipe'' reported that the French anti-doping laboratory LNDD had detected Dynepo in the urine of [[Michael Rasmussen]] during the [[2007 Tour de France]].  Rasmussen was sacked by his own team while leading the Tour, because of irregularities in his reporting of his whereabouts during the lead-up to the tour.  The story also remarked that Dynepo was found in the urine of several other riders, yet criteria for a positive test for Dynepo are not defined.

On July 1, 2009, professional cycling team {{ct|SIL|2009}} announced that [[Thomas Dekker (cyclist)|Thomas Dekker]] was tested positive for dynepo on a test taken on December 24, 2007, while Dekker was riding for {{ct|RAB|2007}}.
<br /><br />
'''Dynepo Pharmaceutical References'''<br /> 
[http://www.ema.europa.eu/humandocs/PDFs/EPAR/dynepo/H-372-PI-en.pdf Dynepo EPAR <sup>(European Public Assessment Report)</sup>, PDF format ], credit [[European Medicines Agency]]
<blockquote>
"This document is a summary of the [[European Public Assessment Report]] (EPAR). It explains how
the Committee for Medicinal products for Human Use (CHMP) assessed the studies performed, to
reach their recommendations on how to use the medicine.
If you need more information about your medical condition or your treatment, read the Package
Leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more
information on the basis of the CHMP recommendations, read the Scientific Discussion (also part
of the EPAR).<br />...''This summary was last updated in 03-2007''."

</blockquote>
{{drug-stub}} 

[[Category:Drugs in sport]]
[[Category:Drugs]]

[[it:Dynepo]]
[[nl:Dynepo]]
[[Category:2Fix]]